Michael Exton, Chief Executive Officer and Director of Lexicon Pharmaceuticals, Inc., filed a Form 4 on November 9, 2026, disclosing an open-market purchase of common stock on November 6, 2026.

Key Highlights

  • Shares acquired: Michael Exton purchased 30,064 shares of Lexicon Pharmaceuticals common stock on November 6, 2026.
  • Weighted average price: The transaction was executed at a weighted average price of $1.6631 per share, with individual purchases ranging from $1.63 to $1.67 per share.
  • Transaction code: The filing reports a "P" (open-market purchase) code for the transaction.
  • Post-transaction ownership: Following the purchase, Exton directly held 328,496 shares of common stock.
  • Role of reporting person: Exton is identified in the filing as both a Director and Chief Executive Officer of the issuer.

Lexicon Pharmaceuticals CEO Discloses Open-Market Common Stock Purchase

According to the Form 4 filed with the SEC on November 9, 2026, Michael Exton, Chief Executive Officer and Director of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), acquired 30,064 shares of the company's common stock on November 6, 2026. The filing identifies the transaction with code "P," indicating an open-market purchase. The reported weighted average price was $1.6631 per share.

The filing notes in its footnote that the shares were purchased across multiple transactions at prices ranging from $1.63 to $1.67 per share. The filing states that Exton "undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote." No Rule 10b5-1 plan checkbox was indicated as applicable to this transaction.

Following the reported transaction, the filing discloses that Exton directly held 328,496 shares of Lexicon Pharmaceuticals common stock. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Michael Exton, Ph.D., and dated November 9, 2026.

What Was Disclosed

The filing disclosed an open-market purchase of 30,064 shares of Lexicon Pharmaceuticals common stock by CEO Michael Exton on November 6, 2026, at a weighted average price of $1.6631, bringing his direct beneficial ownership to 328,496 shares.